We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-8.23%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$351M
AUM Growth
-$99.9M
Cap. Flow
-$14.8M
Cap. Flow %
-4.21%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$3.15M

Top Sells

Rank Stock Value
1
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$11.7M
2
HRMY icon
Harmony Biosciences
HRMY
+$4.31M
3
ELEV
Elevation Oncology
ELEV
+$1.86M
4
PHVS icon
Pharvaris
PHVS
+$34.6K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$277M
$78.5M 22.34%
9,699,925
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.28B
$70.7M 20.12%
1,448,720
-95,764
-6% -$4.31M
VTYX
3
DELISTED
Ventyx Biosciences
VTYX
$61.3M 17.45%
5,011,536
– –
PHVS icon
4
Pharvaris
PHVS
$2.48B
$50.9M 14.48%
2,301,451
-1,859
-0.1% -$34.6K
CINC
5
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$40.4M 11.51%
2,145,035
+164,329
+8% +$3.15M
IMPL
6
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$25.7M 7.32%
2,759,791
– –
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$20.5M 5.84%
2,171,664
– –
ELEV
8
DELISTED
Elevation Oncology
ELEV
$2.61M 0.74%
1,866,339
-741,828
-28% -$1.86M
VRNA
9
DELISTED
Verona Pharma
VRNA
$678K 0.19%
161,897
– –
CMPI
10
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
– –
-3,673,374
Closed -$11.7M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q2 2022 Portfolio in Review

As of Q2 2022, venBio Partners held 10 positions worth $351M, down 22% from $451M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $14.8M in Q2 2022, closing 1 position and reducing 3 holdings. Its most notable exit was Checkmate Pharmaceuticals, Inc. Common Stock, an estimated $11.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, venBio Partners added an estimated $3.15M to CinCor Pharma, Inc. Common Stock.

  • venBio Partners added most to CinCor Pharma, Inc. Common Stock in Q2 2022, an estimated $3.15M increase.
  • venBio Partners's biggest Q2 2022 reduction was Harmony Biosciences, cutting an estimated $4.31M.
  • venBio Partners fully exited Checkmate Pharmaceuticals, Inc. Common Stock in Q2 2022, selling an estimated $11.7M.
  • venBio Partners's ten largest holdings make up 100% of its $351M portfolio in Q2 2022.
  • venBio Partners opened 0 new positions and closed 1 in Q2 2022.
  • venBio Partners's portfolio value fell 22% quarter-over-quarter to $351M.

Based on venBio Partners's 13F filing for Q2 2022, filed 15 Aug 2022.